March 2016, Vol 9, Seventh Annual Payers' Guide

More than 29 million people in the United States have diabetes, the seventh leading cause of mortality and a major cause of stroke, heart disease, kidney failure, blindness, and other serious conditions. As the US population ages and the number of higher-risk minority groups grows, the incidence of diabetes is projected to nearly double from approximately 8 cases per 1000 individuals in 2008 to approximately 15 cases per 1000 in 2050.
Colony-stimulating factors (CSFs) are endogenous glycoproteins that regulate the production and the functioning of infection-protective granulocytes and macrophages. Overall, 2 types of recombinant CSF drugs—granulocyte CSF (filgrastim, pegfilgrastim) and granulocyte-macrophage CSF (sargramostim)—have been prescribed for more than 20 years to stimulate neutrophils and macrophages, primarily in patients with cancer who are undergoing treatment with cytotoxic chemotherapy.
Rheumatoid arthritis (RA) is a systemic, inflammatory form of arthritis that results in joint inflammation, pain, swelling, and stiffness. Although new treatment strategies that focus on early diagnosis, aggressive treatment, and consistent monitoring have helped many patients achieve their goals, RA continues to present clinical and economic challenges to patients, physicians, and payers.
Page 5 of 5
Results 41 - 43 of 43
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME